title: Cyclosporine before PCI in Patients with Acute Myocardial Infarction.
abstract: BACKGROUND
  Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling.
  
  
  METHODS
  In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume.
  
  
  RESULTS
  A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval [CI], 0.78 to 1.39; P=0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups.
  
  
  CONCLUSIONS
  In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.).
authors: From Centre Hospitalier Universitaire (CHU) Arnaud de Villeneuve (T.-T.C.) and Clinique du Millénaire (C.P.), Montpellier, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg (O.M.), CHU de Nimes, Nimes (G.C.), Hôpital Cardiovasculaire Louis Pradel (G. Rioufol, E.B.-C., C.B., I.B., C.J., G.D., N.M., M.O.), Claude Bernard University (G. Rioufol, E.B.-C., C.B., I.B., C.J., G.D., N.M., M.O.), Centre Hospitalier Saint-Joseph et Saint-Luc (J.-F.A.), Clinique de la Sauvegarde (V.M.), Clinique du Tonkin (P.S.), Clinical Investigation Center and Explorations Fonctionnelles Cardiovasculaires (C.B., I.B., C.J., G.D., N.M., M.O.), Lyon, CHU de Tours (D.A.) and Clinique Saint-Gatien (D.B.), Tours, Hôpital Guillaume et René Laennec, Nantes (P.G.), CHU de Rangueil, Toulouse (M.E.), Centre Hospitalier de Pau, Pau (N.D.), Hôpital Haut Lévèque, Bordeaux (P. Coste), Hôpital A. Michallon-CHU de Grenoble, Grenoble (G.V.), Hôpital Henri Duffau, Avignon (M.M.), Centre Hospitalier du Pays d'Aix, Aix-en-Provence (B.J.), Hôpital Gabriel Montpied, Clermont Ferrand (P.M.), Hôpital Charles Nicolle, Rouen (C.T.), Clinique de la Fourcade, Bayonne (J.-N.L.), Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris (P.G.S.), Hôpital du Bocage, Dijon (Y.C.), Centre Hospitalier General, Chartres (G. Range), Centre Hospitalier de Compiègne, Compiègne (J.C.), CHU d'Angers, Angers (F.P.), CHU de Nancy-Brabois, Vandœuvre-lès-Nancy (F.M.), CHU de Mulhouse (O.R.) and Clinique du Diaconat (O.I.), Mulhouse, Centre Hospitalier d'Annecy, Annecy (L.B.), Polyclinique des Fleurs, Ollioules (P.B.), Hôpital de La Cavale Blanche, Brest (M.G.), Clinique Esquirol, Agen (P. Colin, F.D.P.), Institut Jacques Cartier, Massy (M.-C.M.), Centre Hospitalier Henri Mondor, Créteil (J.-L.D.-R.), Hôpital Claude Galien, Quincy sous Sénat (T.U.), Hôpital Pontchaillou, Rennes (H.L.B.), Clinique de l'Ormeau, Tarbes (T.B.), Hôpital de la Côte de Nacre, Caen (G.G.), and Hôpital Cardi
authors: Thien-Tri
authors: TT
authors: Cung
authors: Olivier
authors: O
authors: Morel
authors: Guillaume
authors: G
authors: Cayla
authors: Gilles
authors: G
authors: Rioufol
authors: David
authors: D
authors: Garcia-Dorado
authors: Denis
authors: D
authors: Angoulvant
authors: Eric
authors: E
authors: Bonnefoy-Cudraz
authors: Patrice
authors: P
authors: Guérin
authors: Meier
authors: M
authors: Elbaz
authors: Nicolas
authors: N
authors: Delarche
authors: Pierre
authors: P
authors: Coste
authors: Gerald
authors: G
authors: Vanzetto
authors: Marc
authors: M
authors: Metge
authors: Jean-François
authors: JF
authors: Aupetit
authors: Bernard
authors: B
authors: Jouve
authors: Pascal
authors: P
authors: Motreff
authors: Christophe
authors: C
authors: Tron
authors: Jean-Noel
authors: JN
authors: Labeque
authors: Philippe Gabriel
authors: PG
authors: Steg
authors: Yves
authors: Y
authors: Cottin
authors: Grégoire
authors: G
authors: Range
authors: Jérome
authors: J
authors: Clerc
authors: Marc J
authors: MJ
authors: Claeys
authors: Patrick
authors: P
authors: Coussement
authors: Fabrice
authors: F
authors: Prunier
authors: Frédéric
authors: F
authors: Moulin
authors: Olivier
authors: O
authors: Roth
authors: Loïc
authors: L
authors: Belle
authors: Philippe
authors: P
authors: Dubois
authors: Paul
authors: P
authors: Barragan
authors: Martine
authors: M
authors: Gilard
authors: Christophe
authors: C
authors: Piot
authors: Patrice
authors: P
authors: Colin
authors: Fabien
authors: F
authors: De Poli
authors: Marie-Claude
authors: MC
authors: Morice
authors: Omar
authors: O
authors: Ider
authors: Jean-Luc
authors: JL
authors: Dubois-Randé
authors: Thierry
authors: T
authors: Unterseeh
authors: Hervé
authors: H
authors: Le Breton
authors: Thierry
authors: T
authors: Béard
authors: Didier
authors: D
authors: Blanchard
authors: Gilles
authors: G
authors: Grollier
authors: Vincent
authors: V
authors: Malquarti
authors: Patrick
authors: P
authors: Staat
authors: Arnaud
authors: A
authors: Sudre
authors: Eskil
authors: E
authors: Elmer
authors: Magnus J
authors: MJ
authors: Hansson
authors: Cyrille
authors: C
authors: Bergerot
authors: Inesse
authors: I
authors: Boussaha
authors: Claire
authors: C
authors: Jossan
authors: Geneviève
authors: G
authors: Derumeaux
authors: Nathan
authors: N
authors: Mewton
authors: Michel
authors: M
authors: Ovize
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D021983:Cyclophilins / Q000037:antagonists & inhibitors*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004562:Electrocardiography; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006333:Heart Failure / Q000453:epidemiology; D006801:Humans; D007275:Injections, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009026:Mortality; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy; D062645:Percutaneous Coronary Intervention; D020257:Ventricular Remodeling / Q000187:drug effects*; D000097322:Peptidyl-Prolyl Isomerase D
chemical_list: D021983:Cyclophilins; D016572:Cyclosporine; D004791:Enzyme Inhibitors; C114456:PPID protein, human; D000097322:Peptidyl-Prolyl Isomerase D